SW480 colorectal cancer cells that naturally express Lgr5 are more sensitive to the most common chemotherapeutic agents than Lgr5-negative SW480 cells.

Abstract:

:Leucine-rich repeat containing G protein-coupled receptor 5 (Lgr5) is a colorectal cancer (CRC) stem cell marker. The role of Lgr5-expressing stem cells in resistance to chemotherapy is controversial. The notion that Lgr5-expressing cells are more chemotherapy resistant is supported by some data; other data do not support this notion. We hypothesized that Lgr5-expressing cells would be more chemotherapy sensitive, as Lgr5 is usually a marker of dividing cells. We tested this hypothesis by exploiting two natural variants of SW480 CRC cells: the less-differentiated Lgr5-expressing floating fraction and the more-differentiated Lgr5-depleted attached fraction. We estimated chemotherapy sensitivity using an XTT Cell Proliferation Assay Kit. We confirmed that the detected chemotherapy sensitivity differences were Lgr5-driven by overexpressing Lgr5. SW480 CRC cells that naturally express Lgr5 are those that are floating, and they are more sensitive to the chemotherapeutic compounds irinotecan (maximum difference approximately two times, 0.0001

journal_name

Anticancer Drugs

journal_title

Anti-cancer drugs

authors

Planutis AK,Holcombe RF,Planoutene MV,Planoutis KS

doi

10.1097/CAD.0000000000000270

subject

Has Abstract

pub_date

2015-10-01 00:00:00

pages

942-7

issue

9

eissn

0959-4973

issn

1473-5741

journal_volume

26

pub_type

杂志文章
  • [Current treatment of bladder cancer: from epidemiology to surgical treatment].

    abstract::Urothelial carcinoma of the bladder accounts for over 95% of bladder tumours in France. The incidence of this disease is increasing in industrialised countries. Several types of bladder cancer can be distinguished: (1) superficial tumours which have a risk of recurrence and progression, although conservative treatment...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,评审

    doi:

    authors: Rischmann P

    更新日期:2000-10-01 00:00:00

  • Effects, in an in-vivo model system, of 1,2,3,4-tetrahydroisoquinoline on glioma.

    abstract::The effects of 1-(biphenyl-4-ylmethyl)-1,2,3,4-tetrahydroisoquinoline-6,7-diol (EDL-155) on the growth of glioma was tested in vitro and in vivo. Normal cultured rat astrocytes and C6 rat glioma were used as a differential screen to test the effects of EDL-155. The compound was preferentially cytotoxic for C6 glioma (...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e32830d5887

    authors: Kang GS,Wang XD,Mohler ML,Kirichenko OV,Patil R,Orr WE,Miller DD,Geisert EE

    更新日期:2008-10-01 00:00:00

  • Increased SPK1 expression promotes cell growth by activating the ERK1/2 signaling in non-small-cell lung cancer.

    abstract::Lung cancer remains the leading cause of cancer-associated mortality in China and the world. Increasing numbers of studies have reported that sphingosine kinase 1 (SPK1) is frequently highly expressed in tumors of various origins, including lung cancer, and its high expression contributes toward tumor progression. How...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000733

    authors: Yang Y,Zhao J,Hao D,Wang X,Wang T,Li H,Lv B

    更新日期:2019-06-01 00:00:00

  • Harmol induces apoptosis by caspase-8 activation independently of Fas/Fas ligand interaction in human lung carcinoma H596 cells.

    abstract::The beta-carboline alkaloids are naturally existing plant substances. It is known that these alkaloids have a wide spectrum of neuropharmacological, psychopharmacological, and antitumor effects. Therefore, they have been traditionally used in oriental medicine for the treatment of various diseases including cancers an...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e32832a2dd9

    authors: Abe A,Yamada H

    更新日期:2009-06-01 00:00:00

  • Mutational profile in circulating tumor DNA in a patient affected by low-risk endometrial cancer: predictable tool of relapse?

    abstract::Endometrial cancer is the commonest gynecological cancer, the majority is endometrioid type, diagnosed at an early stage with 69-88% 5-year survival. Low-grade endometrial cancers have low recurrence rates and often do not receive adjuvant therapy; however, a subset of these patients will have poor outcomes and would ...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000963

    authors: Malentacchi F,Turrini I,Zepponi F,Fantappiè G,Sorbi F,Antonuzzo L,Fambrini M,Noci I,Pillozzi S

    更新日期:2020-11-01 00:00:00

  • TUG1 knockdown inhibits the tumorigenesis and progression of prostate cancer by regulating microRNA-496/Wnt/β-catenin pathway.

    abstract::Our study aimed to further investigate the roles and molecular mechanisms of lncRNA taurine upregulated gene 1 (TUG1) in the development and progression of PC. RT-qPCR assay was carried out to measure expression of TUG1, miR-496, together with β-catenin, cyclin D1 and c-myc. Protein levels of β-catenin, cyclin D1 and ...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000882

    authors: Li G,Yang J,Chong T,Huang Y,Liu Y,Li H

    更新日期:2020-07-01 00:00:00

  • Gemcitabine plus cisplatin chemotherapy with concurrent para-toluenesulfonamide local injection therapy for peripherally advanced nonsmall cell lung cancer larger than 3 cm in the greatest dimension.

    abstract::Para-toluenesulfonamide (PTS), active ingredient being PTS, is a new anticancer drug applied through local intratumoral injection. The aim of this phase II clinical trial was to investigate the response and toxicity of standard gemcitabine (GEM) plus cisplatin (CIS) chemotherapy with concurrent intratumoral injection ...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e32832fe48f

    authors: He J,Ying W,Yang H,Xu X,Shao W,Guan Y,Jiang M,Wu Y,Zhong B,Wang D,Tucker S,Zhong N

    更新日期:2009-10-01 00:00:00

  • In-vitro antiproliferative activities and kinase inhibitory potencies of meridianin derivatives.

    abstract::Marine alkaloid meridianin G derivatives, substituted on the pyrimidine ring by aryl groups, were evaluated for their kinase inhibitory potencies and their in-vitro antiproliferative activities. The derivatives were tested toward a panel of nine protein kinases (KDR, IGF-1R, c-Met, RET, c-Src, c-Abl, PKA, CDK2/cyclin ...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e32830ce4d8

    authors: Rossignol E,Debiton E,Fabbro D,Moreau P,Prudhomme M,Anizon F

    更新日期:2008-09-01 00:00:00

  • Intra-abdominal desmoplastic small cell tumors: report of two cases.

    abstract::Two young adults that presented with intra-abdominal desmoplastic small cell tumors (DSCT) without any evidence of a primary site are described. Both cases share the clinical characteristic features of this rare tumor which include predominant intra-abdominal location as initial presentation, nesting pattern of growth...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:

    authors: Liau CT,Yang TS,Wang CH,Hsueh S

    更新日期:1996-02-01 00:00:00

  • Liver X receptor as a drug target for the treatment of breast cancer.

    abstract::Liver X receptor (LXR) has been exploited widely as a drug target in breast cancer treatment, and various mechanisms underlying the effects of LXR in this area are well studied. The activated LXR plays important roles in estrogen receptor α (ERα) breast cancer cells, such as reducing cell proliferation and arresting c...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,评审

    doi:10.1097/CAD.0000000000000348

    authors: Wu Y,Yu DD,Yan DL,Hu Y,Chen D,Liu Y,Zhang HD,Yu SR,Cao HX,Feng JF

    更新日期:2016-06-01 00:00:00

  • Synergistic killing effect of imatinib and simvastatin on imatinib-resistant chronic myelogenous leukemia cells.

    abstract::The antiproliferative effect of simvastatin on tumor cells has been speculated to be by intracellular signal inhibition through 3-hydroxy-3-methylglutaryl acetyl coenzyme A reductase. We examined the killing effect of simvastatin on imatinib-sensitive and resistant chronic myelogenous leukemia (CML) cells (three kinds...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e32835a0fbd

    authors: Oh B,Kim TY,Min HJ,Kim M,Kang MS,Huh JY,Kim Y,Lee DS

    更新日期:2013-01-01 00:00:00

  • A phase II study of an oxaliplatin/vinorelbine/5-fluorouracil combination in patients with anthracycline-pretreated and taxane-pretreated metastatic breast cancer.

    abstract::The aim of this phase II study was to evaluate safety and efficacy of an oxaliplatin/vinorelbine/5-fluorouracil (FON) combination in anthracycline and taxane-pretreated metastatic breast cancer patients. The following treatment was given: on day 1 of a 21-day cycle, oxaliplatin 130 mg/m (2-h intravenous infusion); on ...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/01.cad.0000231475.77159.aa

    authors: Delozier T,Guastalla JP,Yovine A,Levy C,Chollet P,Mousseau M,Delva R,Coeffic D,Vannetzel JM,Zazzi ES,Brienza S,Cvitkovic E

    更新日期:2006-10-01 00:00:00

  • Role of NK-1 and NK-2 tachykinin receptor antagonism on the growth of human breast carcinoma cell line MDA-MB-231.

    abstract::We demonstrate that neurokinin A (NKA) and substance P (SP) play a role in the proliferation of the estrogen receptor-negative (ER-) cell line MDA-MB-231, a human breast carcinoma expressing both NK-1 and NK-2 receptors. In vitro experiments showed that the specific receptor antagonists MEN 11,467 (NK-1) and nepadutan...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-200511000-00007

    authors: Bigioni M,Benzo A,Irrissuto C,Maggi CA,Goso C

    更新日期:2005-11-01 00:00:00

  • Predictive and prognostic value of magnesium serum level in FOLFIRI plus cetuximab or bevacizumab treated patients with stage IV colorectal cancer: results from the FIRE-3 (AIO KRK-0306) study.

    abstract::Magnesium wasting is a frequent side effect of epidermal growth factor receptor (EGFR)-antibody treatment as magnesium-absorption mechanisms are dependent on EGFR signaling. EGFR-inhibition results in decreased renal reabsorption. There is evidence that hypomagnesemia during cetuximab treatment correlates with respons...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000965

    authors: Schulz C,Heinemann V,Heinrich K,Haas M,Holch JW,Fraccaroli A,Held S,von Einem JC,Modest DP,Fischer von Weikersthal L,Kullmann F,Moehler M,Scheithauer W,Jung A,Stintzing S

    更新日期:2020-09-01 00:00:00

  • Adverse events in patients with liver cancer.

    abstract::This study aimed to further the understanding of the incidence of adverse events (AEs) in a population-based representative liver cancer population where there is currently a lack of knowledge. We carried out a retrospective cohort study using data from an administrative claims database between 1 January 2004 and 31 D...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e3283607f4f

    authors: Dreyfus B,Kawabata HM,Gomez-Caminero A

    更新日期:2013-07-01 00:00:00

  • New chemotherapy options for the treatment of malignant gliomas.

    abstract::This review focuses on the recent advances in chemotherapy of malignant gliomas, with special emphasis on the most common primary brain tumor in adults, glioblastoma. The demonstration of the superiority of concomitant and adjuvant temozolomide with standard radiotherapy over radiotherapy alone in patients with newly ...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,评审

    doi:10.1097/CAD.0b013e32801476fd

    authors: Soffietti R,Rudà R,Trevisan E

    更新日期:2007-07-01 00:00:00

  • RNA interference targeting the R2 subunit of ribonucleotide reductase inhibits growth of tumor cells in vitro and in vivo.

    abstract::RNA interference, a posttranscriptional gene-silencing mechanism, has received considerable attention for its potential as a new therapeutic strategy to treat human diseases and conditions including cancer. Various studies have supported a role for the R2 subunit of ribonucleotide reductase in cancer progression and m...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e328013c04f

    authors: Avolio TM,Lee Y,Feng N,Xiong K,Jin H,Wang M,Vassilakos A,Wright J,Young A

    更新日期:2007-04-01 00:00:00

  • The relationship between the antitumor activity and the ribonucleotide reductase inhibitory activity of (E)-2'-deoxy-2'-(fluoromethylene) cytidine, MDL 101,731.

    abstract::(E)-2'-deoxy-2'-(fluoromethylene) cytidine (MDL101,731) is a new deoxycytidine analog which shows potent antitumor activity against several human tumor models. We previously showed that MDL101,731 inhibited human ribonucleotide reductase (RNR) in HeLa S3 human cervical carcinoma cells. Recently, it has been reported t...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-199808000-00011

    authors: Kanazawa J,Takahashi T,Akinaga S,Tamaoki T,Okabe M

    更新日期:1998-08-01 00:00:00

  • Repeat dose study of the novel proapoptotic chemotherapeutic agent alpha-tocopheryloxy acetic acid in mice.

    abstract::Alpha-tocopheryloxy acetic acid (α-TEA) is an ether derivative of vitamin E and has been shown to suppress tumor growth in various murine and human xenograft tumor models, including melanoma, breast, lung, prostate, and ovarian cancers. The purpose of this study was to assess its safety and pharmacokinetics after repe...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e32834f6271

    authors: Hahn T,Akporiaye ET

    更新日期:2012-04-01 00:00:00

  • A retrospective study of paclitaxel combining nedaplatin chemotherapy for esophageal cancer.

    abstract::The aim of this study was to evaluate the efficacy and tolerability of the combination of paclitaxel and nedaplatin in patients with advanced esophageal cancer. Patients (n = 310) with recurrent or metastatic esophageal squamous cell carcinoma, who had a maximum of one previous chemotherapy regimen, were enrolled in t...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000170

    authors: Du J,Hu C,Zhang Y,Hu B,Wang F,Zhang Y

    更新日期:2015-01-01 00:00:00

  • A palladium(II)-saccharinate complex of terpyridine exerts higher anticancer potency and less toxicity than cisplatin in a mouse allograft model.

    abstract::The main aim of this study is to assess the safety and antitumor efficacy of a palladium(II) (Pd)-saccharinate complex with terpyridine. To characterize the Pd(II) complex in vitro, its cytotoxicity was evaluated using a water-soluble tetrazolium salt cell viability assay and the mechanism of cell death was assessed b...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000531

    authors: Cetin Y,Adiguzel Z,Polat HU,Akkoc T,Tas A,Cevatemre B,Celik G,Carikci B,Yilmaz VT,Ulukaya E,Acilan C

    更新日期:2017-09-01 00:00:00

  • 9-ING-41, a small-molecule glycogen synthase kinase-3 inhibitor, is active in neuroblastoma.

    abstract::Advanced stage neuroblastoma is a very aggressive pediatric cancer with limited treatment options and a high mortality rate. Glycogen synthase kinase-3β (GSK-3β) is a potential therapeutic target in neuroblastoma. Using immunohistochemical staining, we observed positive GSK-3β expression in 67% of human neuroblastomas...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000652

    authors: Ugolkov AV,Bondarenko GI,Dubrovskyi O,Berbegall AP,Navarro S,Noguera R,O'Halloran TV,Hendrix MJ,Giles FJ,Mazar AP

    更新日期:2018-09-01 00:00:00

  • A prolonged complete response in a patient with BRAF-mutated melanoma stage IV treated with the MEK1/2 inhibitor selumetinib (AZD6244).

    abstract::In melanoma, the RAS/RAF/MEK/ERK pathway is frequently activated by mutations in BRAF and NRAS. Selumetinib (AZD6244) is an oral, selective, non-ATP-competitive inhibitor of MEK1/2. Here, we describe a patient with metastatic melanoma (T1N2cM1a) with a BRAF V600E mutation. She is currently being treated with selumetin...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e328350737d

    authors: Boers-Sonderen MJ,Desar IM,Blokx W,Timmer-Bonte JN,van Herpen CM

    更新日期:2012-08-01 00:00:00

  • Metformin sensitizes human bladder cancer cells to TRAIL-induced apoptosis through mTOR/S6K1-mediated downregulation of c-FLIP.

    abstract::Metformin, an oral antidiabetic agent, has been reported to potentiate chemotherapeutic-induced cytotoxicity. In this study, we investigated the effects and molecular mechanisms of metformin in sensitizing tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in human bladder cancer cells. ...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000116

    authors: Zhang T,Wang X,He D,Jin X,Guo P

    更新日期:2014-09-01 00:00:00

  • Population pharmacokinetic approach to compare oral and i.v. administration of etoposide.

    abstract::The antitumor effect of etoposide (ETO) may be related to duration of exposure to a relatively low serum level while myelosuppression may be dependent on peak ETO serum levels. With regard to such therapeutic ranges, duration of exposure to predefined plasma ETO concentration ranges and the related AUC (expressed as p...

    journal_title:Anti-cancer drugs

    pub_type: 临床试验,杂志文章

    doi:10.1097/00001813-199910000-00003

    authors: Würthwein G,Krümpelmann S,Tillmann B,Real E,Schulze-Westhoff P,Jürgens H,Boos J

    更新日期:1999-10-01 00:00:00

  • Isoquercitrin isolated from Hyptis fasciculata reduces glioblastoma cell proliferation and changes beta-catenin cellular localization.

    abstract::Isoquercitrin isolated from the aerial parts of Hyptis fasciculata was evaluated according to its capacity to interfere with glioblastoma (Gbm) cell growth. Gbm cells were incubated with isoquercitrin, quercetin, or rutin at concentrations of 25, 50, and 100 mumol/l for 24, 48, and 72 h. Quercetin and rutin affected G...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e32832d1149

    authors: Amado NG,Cerqueira DM,Menezes FS,da Silva JF,Neto VM,Abreu JG

    更新日期:2009-08-01 00:00:00

  • Atypical multi-drug resistance (MDR): low sensitivity of a P-glycoprotein-expressing human T lymphoblastoid MDR cell line to classical P-glycoprotein-directed resistance-modulating agents.

    abstract::Verapamil, cyclosporin A (CsA), the cyclosporin derivative SDZ PSC 833 and the novel cyclopeptolide SDZ 280-446 were tested for their capacity to chemosensitize a P-glycoprotein (Pgp)-expressing multi-drug resistant (MDR) variant of the CEM human T lymphoblastoid cell subline (CCRF ACTD 400+). That MDR-CEM cell sublin...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:

    authors: Jachez B,Loor F

    更新日期:1993-12-01 00:00:00

  • Mitoxantrone and cisplatin in recurrent and/or metastatic salivary gland malignancies.

    abstract::A phase II study was performed to assess the safety and efficacy of mitoxantrone and cisplatin in locally recurrent and/or metastatic carcinomas of the salivary glands. Between May 1997 and March 2001, a total of 14 patients were entered on this trial. All of them had previously undergone radical resection and 10 were...

    journal_title:Anti-cancer drugs

    pub_type: 临床试验,杂志文章

    doi:10.1097/00001813-200206000-00007

    authors: Gedlicka C,Schüll B,Formanek M,Kornfehl J,Burian M,Knerer B,Selzer E,Scheithauer W,Kornek GV

    更新日期:2002-06-01 00:00:00

  • Imatinib mesylate therapy in patients with gastrointestinal stromal tumors and impaired liver function.

    abstract::Hepatic and peritoneal metastases are the most frequent metastatic lesions in patients with gastrointestinal stromal tumors (GIST), and may result in intra- or extrahepatic cholestasis and altered drug metabolism. While the tyrosine kinase inhibitor imatinib, which has been recently shown to represent the treatment of...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-200209000-00010

    authors: Bauer S,Hagen V,Pielken HJ,Bojko P,Seeber S,Schütte J

    更新日期:2002-09-01 00:00:00

  • High incidence of coagualopathy in phase II studies of recombinant tumor necrosis factor in advanced pancreatic and gastric cancers.

    abstract::This multi-center trial was carried out to assess the therapeutic potential of recombinant tumor necrosis factor (rTNF) as the first form of systemic therapy for advanced carcinomas of gastric and pancreatic origin. To be eligible patients were required to have no overt sign of coagulopathy and hepatic function studie...

    journal_title:Anti-cancer drugs

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1097/00001813-199206000-00002

    authors: Muggia FM,Brown TD,Goodman PJ,Macdonald JS,Hersh EM,Fleming TR,Leichman L

    更新日期:1992-06-01 00:00:00